A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...

The four trials also assessed efficacy of the ICS/LABA products. Based on a review of four clinical safety trials, the Food and Drug Administration (FDA) has concluded that medications that contain ...

Patients with chronic obstructive pulmonary disease (COPD) have multiple breathing problems and, at the more severe stages, experience acute exacerbations of COPD up to three times annually. Because ...

Asthma management guidelines advocate a stepwise approach to asthma therapy, including the addition of a long-acting bronchodilator to inhaled steroid therapy at step 3. This is almost exclusively ...

Evidence is lacking, however, to support the combination therapy for mortality (moderate-quality evidence) and exacerbations (low-quality evidence). Tiotropium + LABA/ICS did not increase adverse ...

Disruption of the refill of patients' regular combination inhaled corticosteroid therapy brand may have impacted symptoms and disease control and potentially lead to an increased rate of costly ...

Older adults with coexisting asthma and chronic obstructive pulmonary disease (COPD), known as asthma-COPD overlap, who take fixed-dose combinations of inhaled corticosteroids and long-acting β ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved updates to the SYMBICORT ® (budesonide ...

Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...

GlaxoSmithKline's experimental once-daily lung drug LAMA/LABA showed positive results on Monday from late stage trials in patients with chronic obstructive pulmonary disease (COPD). The Phase III data ...